We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| BELLUS Health Inc | TSX:BLU | Toronto | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 19.48 | 19.46 | 19.52 | 0 | 01:00:00 |
From May 2022 to May 2024
0959 GMT - GSK is among the most mentioned companies across news items over the past six hours, according to Factiva data, after it said it had reached an agreement to buy Canadian late-stage biopharmaceutical company Bellus Health Inc. for $14.75 a share in cash, representing a total equity value of around $2.0 billion. The British pharma major said that through the acquisition it will gain access to camlipixant, a treatment for refractory chronic cough which is currently in phase III development. Accretion to adjusted earnings per share from the acquisition is expected to occur from 2027. It has the potential to deliver significant sales through 2031 and beyond, according to GSK. Dow Jones & Co. owns Factiva. (cecilia.butini@wsj.com)
(END) Dow Jones Newswires
April 18, 2023 06:15 ET (10:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year BELLUS Health Chart |
1 Month BELLUS Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
